This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PharmaLeaders: Generic Manufacturers Benchmark Report - Financial Benchmarking & Competitive Analysis Of The Leading Generic Players In 2013

Table of Contents

1 Table of Contents 61.1 List of Tables 101.2 List of Figures 112 Introduction 132.1 Report Scope 132.2 Upcoming Related Reports 152.3 Recently Published Reports 152.4 GlobalData's Benchmarking Methodology 163 GlobalData Benchmark Rankings 173.1 Sun Pharmaceuticals Emerges as Generics Leader 174 Financial Management 194.1 Competitive Framework 194.2 Overview 194.3 Financial Management: Heat Map 224.4 Financial Metrics 244.4.1 Revenue Leaders 244.4.2 Revenue Laggards 264.4.3 Revenue Growth Leaders 284.4.4 Revenue Growth Laggards 304.4.5 Operating Income Leaders 324.4.6 Operating Income Laggards 334.4.7 Operating Income YTY Growth Leaders 354.4.8 Operating Income YTY Growth Laggards 364.4.9 Operating Margin Leaders 39 4.4.10 Operating Margin Laggards 405 Expense Management 435.1 Competitive Framework 435.2 Overview 435.3 Expense Management: Heat Map 465.4 Expense Metrics 485.4.1 SG&A Spending Leaders 485.4.2 SG&A Spending Laggards 495.4.3 SG&A YTY Change Leaders 515.4.4 SG&A YTY Change Laggards 525.4.5 Operating Expense Leaders 545.4.6 Operating Expense Laggards 556 Capital Management 586.1 Competitive Framework 586.2 Overview 586.3 Competitive Framework: Heat Map 606.4 Capital Management Metrics 616.4.1 Debt-to-Assets Leaders 616.4.2 Debt-to-Assets Laggards 636.4.3 Cash Ratio Leaders 656.4.4 Cash Ratio Laggards 676.4.5 ROI Leaders 696.4.6 ROI Laggards 707 Key Players 727.1 Strategic Analysis of Leading Generics Players 727.1.1 Sun Pharmaceuticals: The Benchmark Leader 727.1.2 Sandoz 767.1.3 Pharmstandard 797.1.4 Teva Pharmaceuticals 817.1.5 Actavis 867.1.6 Mylan 907.1.7 Ranbaxy 937.1.8 Dr. Reddy's 947.1.9 Covidien 95 7.1.10 Hospira 968 Outlook 978.1 Leverage Improvement will Significantly Alter 2013 Benchmark Rankings 978.2 Generic Manufacturers in Emerging Markets will continue to Challenge for Top Spots 979 Appendix 999.1 Bibliography 999.2 Abbreviations 999.3 Research Methodology 1019.3.1 Coverage 1019.3.2 Secondary Research 1029.3.3 Expert Panel Validation 1029.4 About the Authors 1029.4.1 Analyst 1029.4.2 Director of Healthcare Industry Dynamics 1039.4.3 Global Head of Healthcare Research and Consulting 1039.5 About the Industry Dynamics Team 1049.6 About GlobalData 1049.7 Contact Us 1049.8 Disclosure Information 1059.9 Disclaimer 105

List of Tables

Table 1: GlobalData Benchmark Rankings, FY2012 18Table 2: Top 15 Companies FM Composite Scores and Overall FM Score, 2012 22Table 3: Bottom 15 Companies' FM Composite Scores and Overall FM Score, 2012 23Table 4: FY2012 Top Three Revenue Leaders 24Table 5: FY2012 Top Three Revenue Laggards 26Table 6: FY2012 Top Three Revenue Growth Leaders 28Table 7: FY2012 Top Three Revenue Growth Laggards 30Table 8: FY2012 Top Three Operating Income Leaders 32Table 9: FY2012 Top Three Operating Income Laggards 33Table 10: FY2012 Top Three YTY Operating Income Growth Leaders 35Table 11: FY2012 Top Three YTY Operating Income Growth Laggards 36Table 12: FY2012 Top Three Operating Margin Leaders 39Table 13: FY2012 Top Three Operating Margin Laggards 40Table 14: Top 15 Companies' EM Composite Scores and Overall EM Score, 2012 46Table 15: Bottom 15 Companies' EM Composite Scores and Overall EM Score, 2012 47Table 16: FY2012 Top SG&A Spending Leaders as a Percentage of Revenue 48Table 17: FY2012 Top R&D Spending Laggards as a Percentage of Revenue 49Table 18: FY2012 Top SG&A YTY Change Leaders 51Table 19: FY2012 Top SG&A YTY Change Laggards 52Table 20: FY2012 Top Operating Expense Leaders as a Percentage of Revenue 54Table 21: FY2012 Top Operating Expense Laggards as a Percentage of Revenue 55Table 22: Top 15 Companies' CM Composite Scores and Overall CM Score, 2012 60Table 23: Bottom 15 Companies' CM Composite Scores and Overall CM Score, 2012 61Table 24: FY2012 Top Debt-to-Assets Leaders 61Table 25: FY2012 Debt-to-Assets Laggards 63Table 26: FY2012 Cash Ratio Leaders 65Table 27: FY2012 Cash Ratio Laggards 67Table 28: FY2012 ROI Leaders 69Table 29: FY2012 ROI Laggards 70

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.99 -0.02%
FB $99.54 -0.21%
GOOG $678.11 -0.68%
TSLA $148.25 0.18%
YHOO $26.82 -0.85%


Chart of I:DJI
DOW 16,014.38 -12.67 -0.08%
S&P 500 1,852.21 -1.23 -0.07%
NASDAQ 4,268.7630 -14.99 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs